HC Wainwright Reaffirms Buy Rating for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)‘s stock had its “buy” rating reiterated by HC Wainwright in a research report issued on Tuesday,Benzinga reports. They currently have a $9.00 price target on the stock.

Several other research analysts also recently commented on LCTX. Maxim Group decreased their price objective on Lineage Cell Therapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a research note on Friday, January 10th. D. Boral Capital decreased their price objective on Lineage Cell Therapeutics from $3.00 to $2.00 and set a “buy” rating on the stock in a report on Tuesday.

Lineage Cell Therapeutics Price Performance

NYSEAMERICAN:LCTX traded down $0.01 during mid-day trading on Tuesday, hitting $0.64. 379,464 shares of the company’s stock were exchanged, compared to its average volume of 2,166,995. Lineage Cell Therapeutics has a one year low of $0.48 and a one year high of $1.61. The firm has a market capitalization of $141.51 million, a P/E ratio of -5.34 and a beta of 1.21.

Institutional Investors Weigh In On Lineage Cell Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Defender Capital LLC. grew its stake in Lineage Cell Therapeutics by 19.2% in the fourth quarter. Defender Capital LLC. now owns 5,963,348 shares of the company’s stock worth $2,997,000 after purchasing an additional 961,150 shares in the last quarter. Geode Capital Management LLC grew its holdings in Lineage Cell Therapeutics by 2.3% during the 3rd quarter. Geode Capital Management LLC now owns 3,679,280 shares of the company’s stock worth $3,331,000 after acquiring an additional 83,274 shares in the last quarter. Barclays PLC lifted its holdings in Lineage Cell Therapeutics by 311.3% during the third quarter. Barclays PLC now owns 211,300 shares of the company’s stock worth $192,000 after buying an additional 159,924 shares during the period. State Street Corp increased its stake in Lineage Cell Therapeutics by 1.8% during the 3rd quarter. State Street Corp now owns 2,608,352 shares of the company’s stock valued at $2,361,000 after purchasing an additional 45,483 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its position in Lineage Cell Therapeutics by 13.9% in the third quarter. JPMorgan Chase & Co. now owns 677,162 shares of the company’s stock valued at $613,000 after buying an additional 82,864 shares during the last quarter. 62.47% of the stock is owned by institutional investors.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.